Rho Kinase Inhibition with Fasudil in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis—Symptomatic Treatment Potential after Disease Onset

Despite an improved understanding of the genetic background and the pathomechanisms of amyotrophic lateral sclerosis (ALS) no novel disease-modifying therapies have been successfully implemented in clinical routine. Riluzole still remains the only clinically approved substance in human ALS treatment...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Pharmacol
Asıl Yazarlar: Günther, René, Balck, Alexander, Koch, Jan C., Nientiedt, Tobias, Sereda, Michael, Bähr, Mathias, Lingor, Paul, Tönges, Lars
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2017
Konular:
Pharmacology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5281550/
https://ncbi.nlm.nih.gov/pubmed/28197100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00017
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller